{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:22:10Z","timestamp":1788168130005,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.isci.2023.107192","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T22:42:04Z","timestamp":1687387324000},"page":"107192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission"],"prefix":"10.1016","volume":"26","author":[{"given":"Kelly M.","family":"Rausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Barnafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Muratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Patrick","family":"Gorres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-5005","authenticated-orcid":false,"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.107192_bib1","series-title":"World Malaria Report 2021","author":"WHO","year":"2021"},{"key":"10.1016\/j.isci.2023.107192_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4103\/0971-5916.191927","article-title":"Strategies\u00a0& recent development of transmission-blocking vaccines against Plasmodium falciparum","volume":"143","author":"Chaturvedi","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.isci.2023.107192_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2023.107192_bib4","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1242\/jcs.113.19.3419","article-title":"Distinct roles for pbs21 and pbs25 in the in\u00a0vitro ookinete to oocyst transformation of Plasmodium berghei","volume":"113","author":"Sid\u00e9n-Kiamos","year":"2000","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.isci.2023.107192_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2875-4-15","article-title":"Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?","volume":"4","author":"Baton","year":"2005","journal-title":"Malar. J."},{"key":"10.1016\/j.isci.2023.107192_bib6","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/emboj\/20.15.3975","article-title":"P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions","volume":"20","author":"Tomas","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2023.107192_bib7","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1128\/IAI.68.10.5530-5538.2000","article-title":"A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies","volume":"68","author":"Stowers","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.isci.2023.107192_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-3024.2003.00643.x","article-title":"Pfs230: from malaria transmission-blocking vaccine candidate toward function","volume":"25","author":"Williamson","year":"2003","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.isci.2023.107192_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0166-6851(95)02507-3","article-title":"Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes","volume":"75","author":"Williamson","year":"1995","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.isci.2023.107192_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.isci.2023.107192_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1365-2958.2006.05284.x","article-title":"Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production","volume":"61","author":"Eksi","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.isci.2023.107192_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-3024.1994.tb00305.x","article-title":"Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing","volume":"16","author":"Read","year":"1994","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.isci.2023.107192_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S0031182099005041","article-title":"Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230","volume":"119","author":"Healer","year":"1999","journal-title":"Parasitology"},{"key":"10.1016\/j.isci.2023.107192_bib14","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1128\/IAI.05288-11","article-title":"Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48\/45 and Pfs230 in an area of seasonal transmission","volume":"79","author":"Ou\u00e9draogo","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.isci.2023.107192_bib15","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1016\/j.vaccine.2007.02.073","article-title":"Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates","volume":"25","author":"Qian","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2023.107192_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-019-0121-9","article-title":"Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230","volume":"4","author":"Scaria","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2023.107192_bib17","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","author":"Shimp","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2023.107192_bib18","doi-asserted-by":"crossref","first-page":"18243","DOI":"10.1073\/pnas.0608545103","article-title":"Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex","volume":"103","author":"Wu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.107192_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2023.107192_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"Safety and immunogenicity of Pfs25H-EPA\/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.107192_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/iai.65.3.1109-1113.1997","article-title":"A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines","volume":"65","author":"Duffy","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.isci.2023.107192_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107192_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.isci.2023.107192_bib24","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18\u00a0months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2023.107192_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.107192_bib26","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107192_bib27","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2023.107192_bib28","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.isci.2023.107192_bib29","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.vaccine.2020.06.018","article-title":"Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230","volume":"38","author":"Scaria","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2023.107192_bib30","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-021-21955-1","article-title":"A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes","volume":"12","author":"Coelho","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2023.107192_bib31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"A randomized controlled phase 1 trial of malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel\u00ae in healthy Malian adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2023.107192_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/srep11193","article-title":"Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum","volume":"5","author":"Kapulu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2023.107192_bib33","series-title":"A Language and Environment for Statistical Computing","author":"Team","year":"2020"},{"key":"10.1016\/j.isci.2023.107192_bib34","author":"Zaiontz"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223012695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223012695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:00:23Z","timestamp":1788166823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223012695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2589004223012695"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.107192","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.107192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"107192"}}